Last verified: April 20, 2026 · FDA status checked · Pricing verified · Trial data confirmed

Comparison Guide · April 20, 2026

CagriSema vs Zepbound: Should You Wait for CagriSema or Start Zepbound Now? (2026)

Last reviewed: March 8, 2026

By The RX Index Research Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers

CagriSema vs Zepbound at a Glance

This is the one table you need. Everything below expands on it.

Sources: REDEFINE 1 and REDEFINE 2 (NEJM, June 22, 2025); REDEFINE 4 topline (Novo Nordisk press release, Feb 23, 2026); SURMOUNT-5 (NEJM, May 11, 2025); Zepbound Prescribing Information; LillyDirect and Ro pricing pages (verified April 2026).

What We Actually Verified for This Page

We built this page the same way we'd make the decision ourselves — by checking primary sources and flagging anything that couldn't be confirmed.

• ✅CagriSema FDA status: NDA submitted December 18, 2025. Novo Nordisk says a decision is anticipated by late 2026. No public PDUFA target date has been confirmed. (Sources: Novo Nordisk press release, Drugs.com)
• ✅REDEFINE 4 head-to-head result: Topline released February 23, 2026 — CagriSema 23.0% vs Zepbound 25.5% at 84 weeks (adherent estimand); primary endpoint of non-inferiority was not met. (Sources: Novo Nordisk press release, Healio, BioPharma Dive)
• ✅REDEFINE 1 weight loss data: Peer-reviewed in the New England Journal of Medicine, June 22, 2025.
• ✅SURMOUNT-5 head-to-head data (Zepbound vs Wegovy): Peer-reviewed in NEJM, May 11, 2025.
• ✅Zepbound pricing: Pulled directly from Lilly's Zepbound Self Pay Journey Program terms and zepbound.lilly.com/savings, checked April 2026. Savings card expires 12/31/2026.
• ⚠️[NOT ANNOUNCED] CagriSema launch price: Novo Nordisk has not published any pricing. Industry analyst speculation ranges from $1,300–$1,500/month based on Wegovy's list price, but this is an estimate, not a verified fact. We'll update when Novo announces.
• ⚠️[INCONSISTENT SOURCES] Ro membership pricing: Ro's canonical pricing page shows $39 first month, then $74/month on annual prepay or $149/month monthly. Some secondary pages show $45/$145. We treat the pricing page as the correct quote and recommend verifying at checkout.

If anything on this page is ever wrong, it's because something changed after our last verification. We update monthly and on major news.

The Head-to-Head Data That Changed This Comparison

Why REDEFINE 4 Matters More Than Any Other Comparison

Separate trials can't be compared cleanly. The protocols differ, the patients differ, the durations differ. REDEFINE 4 was the first time CagriSema and Zepbound were put into the same trial, given to the same type of patients, at the same doses, for the same 84 weeks. It's the only direct evidence we have.

Novo's own chief scientific officer, Martin Holst Lange, tried to frame the result positively, saying CagriSema “has the potential to be the first GLP-1/amylin-combination product to reach the market.” That's probably true. It doesn't change the math: in the same trial, Zepbound produced more weight loss.

The Full Picture Across Every Phase 3 Trial

Here's every head-to-head and placebo-controlled Phase 3 trial for these two drugs in one table. This is the data most comparison pages haven't assembled.

Note: Cross-trial comparisons are indicative, not definitive. REDEFINE 4 (CagriSema vs Zepbound) and SURMOUNT-5 (Zepbound vs Wegovy) are the only direct head-to-head trials.

Two things jump out:

1. CagriSema beats semaglutide-alone and cagrilintide-alone. The combination does add something.
2. When the combination goes head-to-head against Zepbound's dual-receptor mechanism, Zepbound still produces more weight loss.

Is CagriSema FDA Approved — and When Might It Actually Be Available?

What “Not Yet Approved” Means for You Right Now

Novo filed in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials. The FDA standard review clock is 10 months from acceptance, which is why Novo publicly points to “late 2026.” That's the official position — the specific review target date hasn't been disclosed.

Even if CagriSema clears the FDA, Novo still has to get the drug into pharmacies. And CagriSema has a manufacturing wrinkle Zepbound doesn't: its two active ingredients (cagrilintide and semaglutide) can't be dissolved together. They have to be produced separately and delivered in a dual-chamber pen. Leerink Partners analysts have flagged Novo's manufacturing capacity as a known bottleneck. When Zepbound launched in late 2023, it took well into 2024–2025 for supply to normalize. CagriSema's ramp will almost certainly be slower.

Can You Get CagriSema Right Now Through Any Legal Path?

Realistically, the only access path for a consumer today is a clinical trial. ClinicalTrials.gov lists CagriSema studies in the REDEFINE and REIMAGINE programs; status and eligibility vary by study. Enrollment requires specific BMI, comorbidity, and geographic criteria.

What you cannot legally do: buy cagrilintide from a compounding pharmacy, a “research chemical” vendor, or a cross-border pharmacy. The FDA's current position is that compounded cagrilintide products do not qualify for the exemptions in sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act, and the agency has warned against “research use only” products marketed for human use.

If you need treatment in the next 12 months, the REDEFINE timeline is telling you to act on what's available now. For a deeper dive on the mechanism, trial design, and pipeline, see our What Is CagriSema? guide.

How CagriSema and Zepbound Work (and Why the Difference Matters Less Than You'd Think)

Tirzepatide's Mechanism in One Paragraph

Tirzepatide hits two appetite-regulating hormones your body already uses. GLP-1 slows gastric emptying and blunts hunger. GIP amplifies those effects and appears to influence fat metabolism in ways researchers are still mapping. The combined effect produces more weight loss than activating GLP-1 alone — which is why Zepbound beats Wegovy in head-to-head data.

CagriSema's Mechanism in One Paragraph

CagriSema takes semaglutide — the same GLP-1 drug in Wegovy — and pairs it with cagrilintide, a long-acting amylin analogue. Amylin works through different brain pathways than GLP-1, targeting satiety and food-reward circuits. Novo's hypothesis was that stacking a different mechanism on top of GLP-1 would beat the dual GLP-1/GIP approach.

It beat semaglutide alone cleanly — in REDEFINE 1, CagriSema produced 22.7% weight loss vs 16.1% for semaglutide alone. Real improvement. It just didn't beat Zepbound.

Why Mechanism Alone Shouldn't Decide Your Choice

A lot of comparison pages go deep on GLP-1 vs GIP vs amylin and leave you thinking the “better mechanism” should pick your drug. The only thing that actually matters for your weight-loss outcome is what the drug does in real patients, over real durations, measured by trials. On that scoreboard, Zepbound produces more weight loss. Mechanism explanations are interesting. They don't change the numbers.

CagriSema vs Zepbound Side Effects Compared

CagriSema Side Effects from Trials

From REDEFINE 1 (N=2,108 on CagriSema):

Discontinuation due to adverse events: 5.9% for CagriSema vs 3.5% for placebo (REDEFINE 1). In REDEFINE 2 (T2D patients), discontinuation ran higher at 8.4%. Note: only about half of CagriSema participants reached the highest dose in REDEFINE 1.

Zepbound Side Effects from Trials

From SURMOUNT-5 (N=374 on tirzepatide):

• ~76.7% experienced at least one adverse event
• GI events (nausea, diarrhea, constipation, vomiting) were most common
• 2.7% discontinued due to GI events (vs 5.6% on Wegovy)
• 4.8% experienced a serious adverse event
• 89.3% of tirzepatide patients reached at least one 15 mg dose

Boxed Warning and Contraindications

Zepbound's FDA-approved label carries a boxed warning about risk of thyroid C-cell tumors based on rodent studies. Label contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), or known serious hypersensitivity to tirzepatide or any excipients. Pregnancy, pancreatitis history, severe GI disease, and diabetic retinopathy are warnings and precautions — real conversations to have with your prescriber.

CagriSema is investigational and doesn't yet have an FDA-approved label or a defined boxed-warning profile. Novo has said the safety profile in REDEFINE trials is consistent with the GLP-1 class, but the formal label language won't exist until the FDA acts.

Side-effect profiles look similar enough that this probably isn't the tie-breaker you were hoping for. If you have a strong history of GI issues, stomach surgery, gastroparesis, or pancreatitis, that's a conversation to have with your prescriber before starting either drug.

Zepbound Cost, CagriSema Cost, and the Real Price of Waiting

Zepbound — Verified Pricing as of April 2026

LillyDirect Self Pay Journey Program (single-dose vials or KwikPen):

The 45-day rule is the part most people miss. Set a calendar reminder at day 30–35 of each supply, or that month costs more.

Through Ro (Our Primary Recommended Path for FDA-Approved Zepbound Access)

Ro carries both Zepbound pen and Zepbound KwikPen.

• Ro Body membership: $39 for the first month, then as low as $74/month on annual prepay or $149/month monthly (membership only; medication billed separately).
• Medication cost through Ro: matches LillyDirect self-pay pricing if you're cash-pay. If you have commercial insurance, Ro runs a free GLP-1 Insurance Coverage Checker and handles prior authorization via their insurance concierge.

What you get with Ro that you don't get direct-to-consumer: a US-licensed clinician reviewing your history, insurance coverage navigation, prior-authorization handling, and ongoing clinical support between refills. Pricing verified April 2026; recommend verifying at checkout.

Want a deeper pricing breakdown? See our Ro vs LillyDirect comparison and the full Zepbound Savings Card guide.

CagriSema Pricing — What We Know, Which Is Nothing Official

Novo Nordisk has not announced pricing or launch economics for CagriSema. Industry analysts have speculated a range of $1,300–$1,500/month based on Wegovy's list price of about $1,349, but that's a projection, not a verified number. We'll update when Novo publishes.

The Real Cost of Waiting (for Most People)

If cost was your reason for considering waiting, the math almost certainly doesn't support it. Even if CagriSema launches below analyst expectations, the savings-card economics for Zepbound are hard to beat — and you'd be giving up a year of progress to wait for something that already showed up behind in the trial.

Here's the One Honest Downside of Starting Zepbound Now

Zepbound is a weekly injection. Not a pill. An auto-injector pen you use once a week.

For most people who've seen the pen, used it once, and kept going, the injection turns out to be much less of a deal than they feared. But if you have a genuine, non-negotiable aversion to needles, Zepbound is going to be harder than a daily pill would be.

If needles are a true dealbreaker, there are now FDA-approved pill options:

• Foundayo (orforglipron) — FDA-approved April 1, 2026. Once-daily pill, no food or water restrictions, any time of day. $149/month starter self-pay, as low as $25/month with commercial insurance and the Foundayo savings card. Weight loss at the highest dose: 12.4% over 72 weeks in ATTAIN-1 (adherent estimand). See our Orforglipron vs Zepbound guide.
• Wegovy pill (oral semaglutide 25 mg) — FDA-approved December 2025 for weight loss. Once-daily pill with strict morning fasting rules. About $149/month starter self-pay. OASIS-4 trial showed approximately 16.6% weight loss at the highest dose. See our Wegovy pill vs Zepbound guide.

Here's why the injection isn't usually a dealbreaker for readers on this specific page: the injection is the reason Zepbound produces the weight loss it does. Injectable GLP-1 drugs consistently outperform oral versions in clinical trials. Weekly injection in exchange for the strongest FDA-approved weight-loss result available today is, for most people comparing CagriSema and Zepbound, a trade worth making.

Should You Wait for CagriSema or Start Zepbound Now?

Start Zepbound Now If…

• ✓Your BMI is ≥30, or ≥27 with a weight-related condition (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease)
• ✓You want the strongest FDA-approved weight-loss medication available in 2026
• ✓You're willing to do a weekly injection
• ✓You have commercial insurance (even if prior authorization will be required) OR you can budget $299–$449/month
• ✓You don't have a Zepbound label contraindication: a personal or family history of medullary thyroid carcinoma, MEN2, or known serious hypersensitivity to tirzepatide

You're Probably Fine Waiting If…

• →You're already enrolled in a CagriSema clinical trial and it's working
• →You don't need treatment in the next 12+ months and specifically want to watch the pipeline before deciding
• →You're choosing between Zepbound and CagriSema as an intellectual exercise, not a clinical decision

If cost is your reason for wanting to wait, revisit the math above. CagriSema almost certainly won't be cheaper.

You Might Want a Different Path Entirely If…

• Needles are an absolute dealbreaker. → Orforglipron vs Zepbound and Wegovy pill vs Zepbound.
• Insurance is the problem, you're on Medicare, or your plan excludes weight-loss drugs. → Does Medicare cover Zepbound? and the Medicare GLP-1 Bridge program launching July 2026.
• You want maximum flexibility — FDA-approved AND lower-cost cash-pay options in one account. Eden carries both FDA-approved Zepbound and compounded tirzepatide (a separate product type, not FDA-approved as a finished medication, prepared by a licensed pharmacy) under one membership. Compounded tirzepatide typically costs less than brand Zepbound. For readers comparing CagriSema and Zepbound specifically, the brand-name path is usually the closer fit — but this option exists if budget flexibility matters to you. See Eden's options.
• You're overwhelmed and want a personal match. → Take our free 60-second GLP-1 matching quiz and we'll recommend a specific path based on your situation.

What Real Ro Patients Say About the Experience

We looked for legitimate, attributable testimonials about the Zepbound experience — not general weight-loss endorsements or outcome claims we can't substantiate.

Disclosure: Ro states that branded GLP-1 members featured on their reviews page were paid for their testimonials. We feature them because they describe the service experience — insurance handling, medication sourcing, prior-authorization support — not to imply typical weight-loss results. Individual results vary; all weight-loss numbers on this page come from peer-reviewed clinical trials.

Frequently Asked Questions

Methodology

We compared CagriSema and Zepbound using:

• Peer-reviewed Phase 3 trial data from the New England Journal of Medicine: REDEFINE 1 (June 2025), REDEFINE 2 (June 2025), SURMOUNT-1 (2022), SURMOUNT-5 (May 2025)
• Topline head-to-head data from REDEFINE 4 (Novo Nordisk press release, February 23, 2026) — the only direct CagriSema-vs-Zepbound trial
• FDA-approved Prescribing Information for Zepbound (tirzepatide)
• Manufacturer press releases and investor communications from Novo Nordisk and Eli Lilly
• Current pricing pulled from LillyDirect, Ro, and the Zepbound Savings Program pages
• Regulatory status from FDA.gov and Drugs.com

We separated three kinds of claims: commercial facts (pricing, availability, insurance terms), medical and regulatory facts (FDA status, trial outcomes, safety profile), and editorial judgments (such as “most people should start Zepbound now”). Commercial facts are timestamped and re-verified monthly. Editorial judgments are clearly framed as our conclusions based on the verified data.

If any claim on this page is ever incorrect, email us at editor@therxindex.com and we'll update within 48 hours.

Sources

1. Novo Nordisk press release, “CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity — the primary endpoint was not achieved,” February 23, 2026.
2. Garvey WT, et al. “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, June 22, 2025.
3. Davies MJ, et al. “Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.” NEJM, June 22, 2025.
4. Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” NEJM, May 11, 2025.
5. Novo Nordisk press release, “Novo Nordisk files for FDA approval of CagriSema,” December 18, 2025.
6. Zepbound (tirzepatide) Prescribing Information, Eli Lilly and Company, 2026.
7. Zepbound Self Pay Journey Program Terms and Conditions, Eli Lilly, verified April 2026.
8. zepbound.lilly.com/savings — Zepbound Savings Card terms, verified April 2026.
9. Ro weight loss pricing page (ro.co/weight-loss/pricing/), verified April 2026.
10. American Diabetes Association Scientific Sessions 2025, REDEFINE 1 and REDEFINE 2 presentations.
11. Eli Lilly press release, “FDA approves Lilly's Foundayo (orforglipron),” April 1, 2026.
12. Drugs.com, “CagriSema FDA Approval Status,” updated February 2026.